KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Return on Sales (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Return on Sales for 15 consecutive years, with 0.02% as the latest value for Q4 2025.

  • Quarterly Return on Sales fell 11.0% to 0.02% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.05% through Dec 2025, down 17.0% year-over-year, with the annual reading at 0.05% for FY2025, 17.0% down from the prior year.
  • Return on Sales for Q4 2025 was 0.02% at Supernus Pharmaceuticals, up from 0.23% in the prior quarter.
  • The five-year high for Return on Sales was 0.22% in Q3 2024, with the low at 0.23% in Q3 2025.
  • Average Return on Sales over 5 years is 0.05%, with a median of 0.04% recorded in 2021.
  • The sharpest move saw Return on Sales soared 32bps in 2024, then plummeted -45bps in 2025.
  • Over 5 years, Return on Sales stood at 0.02% in 2021, then skyrocketed by 892bps to 0.15% in 2022, then crashed by -95bps to 0.01% in 2023, then soared by 1176bps to 0.09% in 2024, then crashed by -122bps to 0.02% in 2025.
  • According to Business Quant data, Return on Sales over the past three periods came in at 0.02%, 0.23%, and 0.14% for Q4 2025, Q3 2025, and Q2 2025 respectively.